Halted plant drove Sanitas in red in first quarter
This article was originally published in Scrip
Executive Summary
Consolidated sales at Lithuania's largest manufacturer of generic pharmaceuticals Sanitas decreased by around one third to Lt64 million ($26.4 million) in the first quarter of this year, and its domestic sales fell by more than 40% to Lt2.6 million.